The active substance of Volibris is ambrisentan, an anti-hypertensives medicinal product (C02KX02). Volibris is indicated for the treatment of patients with pulmonary arterial hypertension (PAH) classified as WHO
Neoclarityn and Aerius are indicated for the relief of symptoms associated with chronic idiopathic urticaria and allergic rhinitis.
Filgrastim and Tevagrastim are indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy
Forsteo is intended for the treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture.
Biograstim is a biological medicinal product similar to the reference product Neupogen authorized in the EU. Studies have shown Biograstim to have a comparable quality, safety and efficacy
The pooled-patient data revealed that daily use of the NESS L300 neuroprosthesis over a 12-month period enabled patients experiencing chronic hemiparesis and foot drop following stroke or traumatic
The MSA is developed as a simple blood test that identifies and measures the amount of Mammastatin in women. The MSA is a risk-assessment tool intended to be
The European Commission is now expected to grant marketing authorization for this product, which will be marketed in the EU by Teva under the brand name TevaGrastim. G-CSF
To date, four systems have been shipped in anticipation of placing them in hospitals throughout the country. It is anticipated that Misonix and MD International will enter into
The CHMP recommendation will now be forwarded to the European Commission for final marketing approval, which typically occurs within 60 to 90 days. Once the product receives its
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.